Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - linezolid, quantity: 600 mg - tablet - excipient ingredients: croscarmellose sodium; hypromellose; magnesium stearate; purified talc; titanium dioxide; ethylcellulose; diethyl phthalate; microcrystalline cellulose; povidone; silicon dioxide - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. it has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - linezolid, quantity: 600 mg - tablet - excipient ingredients: diethyl phthalate; microcrystalline cellulose; hypromellose; titanium dioxide; magnesium stearate; povidone; croscarmellose sodium; ethylcellulose; silicon dioxide; purified talc - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. it has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - linezolid, quantity: 600 mg - tablet - excipient ingredients: silicon dioxide; diethyl phthalate; hypromellose; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; povidone; magnesium stearate; purified talc; ethylcellulose - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid is active against gram-positive bacteria only. it has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - linezolid - oral tablet - 600mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - linezolid - oral tablet - 600mg

United States - English - NLM (National Library of Medicine)

american health packaging - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 600 mg

United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 2 mg in 1 ml

United States - English - NLM (National Library of Medicine)

american health packaging - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. linezolid is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [see warnings and precautions (5.4)]. nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [see clinical studies (14)]. community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies (14) ]. complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by staphylococcus aureus (methicillin-susceptible and -resistant isolat

United States - English - NLM (National Library of Medicine)

chartwell rx, llc - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. linezolid is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [ see warnings and precautions (5.4) ]. nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [ see clinical studies (14) ]. community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [ see clinical studies (14) ]. complicated skin and skin structure infections, including diabetic foot infections,

United States - English - NLM (National Library of Medicine)

celltrion usa, inc. - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. linezolid is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [see warnings and precautions (5.4) ]. nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [see clinical studies (14) ]. community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies (14) ]. complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus pyogenes , or strept